Post-Traumatic Stress Disorder Pipeline Therapeutics Development Review H2 2015

Press Release   •   Dec 03, 2015 07:35 EST

This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Post-Traumatic Stress Disorder” addition with 37 market data tables and 15 figures, spread across 128 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

Addex Therapeutics Ltd, Azevan Pharmaceuticals, Inc., Catalyst Pharmaceutical Partners, Inc., Eli Lilly and Company, HolsboerMaschmeyer NeuroChemie GmbH, Humanetics Corporation, Intra-Cellular Therapies, Inc., Marinus Pharmaceuticals, Inc., Neuralstem, Inc., Neurocrine Biosciences, Inc., NeuroNascent, Inc., Omeros Corporation, Otsuka Holdings Co., Ltd., Pfizer Inc., Polleo Pharma Limited, Synchroneuron Inc., Tonix Pharmaceuticals Holding Corp. and Vanda Pharmaceuticals Inc.

Drugs Profile Discussed in this Research:

acamprosate calcium SR, ADX-71743, AM-3506, brexpiprazole, CPP-115, Drug for Post-Traumatic Stress Disorders, Drugs to Inhibit FAAH for CNS Disorders, Drugs to Modulate NPSR for Anxiety Disorder, ganaxolone, HL-9001, IC-87201, iloperidone, ITI-007, NNI-351, NSI-189, PF-04457845, Rycal, S-107, Small Molecule to Target GPR151 for CNS Diseases, Small Molecule to Target GPR83 for CNS and Immunological Disorders, Small Molecules for Post-Traumatic Stress Disorder, Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders, Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders, Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder, Small Molecules to Antagonize TLR-4 for CNS Disorders, SRX-246, TNX-102, Vaccine for Post-Traumatic Stress Disorder and Depression, verucerfont, vigabatrin and ZL-006

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Mental Illness Drugs Market.

People fail to function properly when they are suffering from mental troubles. Some of these disorders may be very serious like schizophrenia while there are others which may not be so pronounced. Thus, the severity of the different troubles is likely to vary and so you would have to be very careful while dealing with such patients. Some of the patients may lose the contact with reality as they live in their own imaginary world.

There are a few mental illness drugs that can be used to treat such problems. There cannot be any assurance that these drugs are bound to work because most mental illness is a behavioural disorder and the participation of the patient shall play a crucial role in deciding the efficiency of the mental illness drugs that would be used. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.